Instruction 1(b).

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject	
to Section 16. Form 4 or Form 5	
obligations may continue. See	

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Angotti Vincent J.						2. Issuer Name and Ticker or Trading Symbol ACELRX PHARMACEUTICALS INC									ationship all app Direc	licable)	,			
(Last)	(Fir	et) (N	Middle)		ACI	ACRX]									Office	er (give title		Other (specify	
C/O ACELRX PHARMACEUTICALS, INC.						3. Date of Earliest Transaction (Month/Day/Year) 02/06/2022								Chief Executive Officer						
25821 INDUSTRIAL BLVD., SUITE 400					4 15	A 16 Assessment Date of Ocioinal Filled (Marsh C. 2011)								C. ladicidual or laint/Croup Filing (Chaple Annih - Lin						
(Street)					4. 11 /	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)						
HAYWARD CA 94545												X Form filed by One Reporting Person								
,													Form filed by More than One Reporting Person							
(City)	(Sta	ate) (2	Zip)																	
		Table	I - No	on-Deriva	tive S	Secui	rities	Acc	quirec	l, Dis	sposed of	, or E	Benefic	cially	Own	ed				
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/					Execution Date,						Acquired (A) or (D) (Instr. 3, 4 a		and 5) Securit Benefi		ties cially I Following	Form (D) o		7. Nature of Indirect Beneficial Ownership		
									Code	v	Amount	(A) o (D)	Price	•	Transa	action(s) 3 and 4)			(Instr. 4)	
Common Stock 02/06/20)22				F		27,318(1)	D	\$0.4	4312 616		,628(2)(3)		D		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	tive Conversion Date Execution Date, or Exercise (Month/Day/Year) if any		4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		Expira	e Exerc ation D h/Day/		7. Title and Amount of Securities Underlying Derivative Security (Inst 3 and 4)				9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)			
					Code	v	(A)	(D)	Date Exerc	isable	Expiration Date	Title	Amount or Number of Shares							

Explanation of Responses:

- 1. Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs.
- 2. Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.
- 3. Balance includes non-reportable acquisition of 6,966 shares of Common Stock through the Company's Employee Stock Purchase Plan.

Remarks:

/s/ Martha Adler, Attorney-In-

Fact

02/07/2022

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.